Cancer patients get lifeline to keep taking drug That's working
NCT ID NCT02934568
Summary
This study allows patients with advanced solid tumors who are already benefiting from the cancer drug ribociclib to continue receiving it after their original clinical trial has ended. The purpose is to provide continued access to treatment while monitoring safety. Participants must have been in a previous Novartis-sponsored ribociclib study and still be responding well to the medication.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CONTINUED ACCESS TO STUDY TREATMENT(S), CANCERS WITH A MASS, BULKY TUMOR, NODULE, LUMP, ADVANCED CANCER, ADVANCED SOLID TUMORS, ADVANCED SOLID MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Broome Oncology
Johnson City, New York, 13790, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Novartis Investigative Site
Lyon, 69373, France
-
Novartis Investigative Site
Villejuif, 94800, France
-
Novartis Investigative Site
Cologne, North Rhine-Westphalia, 50937, Germany
-
Novartis Investigative Site
Singapore, 119228, Singapore
-
Novartis Investigative Site
Madrid, 28041, Spain
-
Novartis Investigative Site
Madrid, 28050, Spain
-
Novartis Investigative Site
Tainan, 704302, Taiwan
-
Novartis Investigative Site
Taipei, 10002, Taiwan
-
St Jude Childrens Research Hospital
Memphis, Tennessee, 38105, United States
-
The Regents of the Uni of Michigan
Ann Arbor, Michigan, 48109-5930, United States
-
University Of Alabama At Birmingham
Birmingham, Alabama, 35294-3300, United States
Conditions
Explore the condition pages connected to this study.